JP2005508333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508333A5 JP2005508333A5 JP2003530319A JP2003530319A JP2005508333A5 JP 2005508333 A5 JP2005508333 A5 JP 2005508333A5 JP 2003530319 A JP2003530319 A JP 2003530319A JP 2003530319 A JP2003530319 A JP 2003530319A JP 2005508333 A5 JP2005508333 A5 JP 2005508333A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- glutathione
- disorder
- brain
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 30
- 108010024636 Glutathione Proteins 0.000 claims 15
- 229960003180 glutathione Drugs 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 239000002243 precursor Substances 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 208000028017 Psychotic disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 5
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 4
- 229960004308 acetylcysteine Drugs 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 230000004060 metabolic process Effects 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 230000005714 functional activity Effects 0.000 claims 3
- 210000005171 mammalian brain Anatomy 0.000 claims 3
- 208000017194 Affective disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000002545 drug psychosis Diseases 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32506101P | 2001-09-27 | 2001-09-27 | |
| PCT/AU2002/001320 WO2003026684A1 (en) | 2001-09-27 | 2002-09-26 | Modulation of physiological processes and agents useful for same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010121582A Division JP2010215646A (ja) | 2001-09-27 | 2010-05-27 | 生理学的過程の調節およびこれに有用な薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508333A JP2005508333A (ja) | 2005-03-31 |
| JP2005508333A5 true JP2005508333A5 (enExample) | 2005-12-22 |
| JP4684553B2 JP4684553B2 (ja) | 2011-05-18 |
Family
ID=23266273
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530319A Expired - Fee Related JP4684553B2 (ja) | 2001-09-27 | 2002-09-26 | 生理学的過程の調節およびこれに有用な薬剤 |
| JP2010121582A Withdrawn JP2010215646A (ja) | 2001-09-27 | 2010-05-27 | 生理学的過程の調節およびこれに有用な薬剤 |
| JP2013149286A Expired - Fee Related JP5736421B2 (ja) | 2001-09-27 | 2013-07-18 | 生理学的過程の調節およびこれに有用な薬剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010121582A Withdrawn JP2010215646A (ja) | 2001-09-27 | 2010-05-27 | 生理学的過程の調節およびこれに有用な薬剤 |
| JP2013149286A Expired - Fee Related JP5736421B2 (ja) | 2001-09-27 | 2013-07-18 | 生理学的過程の調節およびこれに有用な薬剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20050032708A1 (enExample) |
| EP (1) | EP1438063B1 (enExample) |
| JP (3) | JP4684553B2 (enExample) |
| AT (1) | ATE468129T1 (enExample) |
| AU (1) | AU2002333018B2 (enExample) |
| CA (1) | CA2461703C (enExample) |
| DE (1) | DE60236446D1 (enExample) |
| DK (1) | DK1438063T3 (enExample) |
| ES (1) | ES2346859T3 (enExample) |
| WO (1) | WO2003026684A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057983A1 (en) * | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
| WO2005017094A2 (en) * | 2003-08-19 | 2005-02-24 | Bioadvantex Pharma Inc. | N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| AU2007308742A1 (en) * | 2006-10-23 | 2008-05-02 | The Mental Health Research Institute Of Victoria | Combination therapy |
| US7829709B1 (en) * | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| WO2009100431A1 (en) * | 2008-02-07 | 2009-08-13 | Marquette University | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
| US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
| AU2010248758A1 (en) * | 2009-05-15 | 2011-11-24 | Intermune, Inc. | Methods of treating HIV patients with anti-fibrotics |
| US20120041066A1 (en) * | 2010-08-16 | 2012-02-16 | Lombard Jay L | Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| US20120270860A1 (en) * | 2011-04-19 | 2012-10-25 | Gihyun Yoon | Methods for treating or preventing alcohol-related disorders or craving-related disorders |
| JP6170166B2 (ja) | 2012-10-30 | 2017-07-26 | 協和発酵バイオ株式会社 | 脳機能低下の予防または改善剤 |
| DK3066089T3 (da) | 2013-11-08 | 2020-01-27 | Promentis Pharm Inc | Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser |
| JP2017534673A (ja) * | 2014-09-15 | 2017-11-24 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 精神病性障害を治療するための方法および組成物 |
| EP3858344A4 (en) * | 2018-09-28 | 2022-07-06 | Keio University | MARKERS FOR EVALUATION OF SENSITIVITY TO AN ANTI-CANCER COMBINATION AGENT |
| CN114786689A (zh) * | 2019-11-18 | 2022-07-22 | 雀巢产品有限公司 | 用于在脑健康中使用的谷胱甘肽增强的组合物和方法 |
| FR3119093B3 (fr) * | 2021-01-27 | 2023-02-10 | Nestle Sa | Compositions et procedes pour une utilisation dans l’augmentation de la performance motivationnelle |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5922765A (en) * | 1996-01-18 | 1999-07-13 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength |
| US5874468A (en) * | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6149925A (en) * | 1998-11-05 | 2000-11-21 | Color Access, Inc. | Topical compositions for enhancing glutathione production |
| US6329430B1 (en) * | 1999-08-18 | 2001-12-11 | Thomas Jefferson University | Modulation of N-methyl-D-aspartate receptor responses with S-substituted derivatives of glutathione |
| US20020002146A1 (en) * | 2000-02-11 | 2002-01-03 | Halevie-Goldman Brian D. | Compositions and methods for the production of S-adenosylmethionine within the body |
| US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB2368339B (en) * | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
-
2002
- 2002-09-26 DK DK02799377.3T patent/DK1438063T3/da active
- 2002-09-26 ES ES02799377T patent/ES2346859T3/es not_active Expired - Lifetime
- 2002-09-26 JP JP2003530319A patent/JP4684553B2/ja not_active Expired - Fee Related
- 2002-09-26 AU AU2002333018A patent/AU2002333018B2/en not_active Ceased
- 2002-09-26 US US10/491,061 patent/US20050032708A1/en not_active Abandoned
- 2002-09-26 AT AT02799377T patent/ATE468129T1/de not_active IP Right Cessation
- 2002-09-26 CA CA2461703A patent/CA2461703C/en not_active Expired - Fee Related
- 2002-09-26 DE DE60236446T patent/DE60236446D1/de not_active Expired - Lifetime
- 2002-09-26 EP EP02799377A patent/EP1438063B1/en not_active Revoked
- 2002-09-26 WO PCT/AU2002/001320 patent/WO2003026684A1/en not_active Ceased
-
2010
- 2010-05-27 JP JP2010121582A patent/JP2010215646A/ja not_active Withdrawn
-
2012
- 2012-11-09 US US13/673,327 patent/US20130065961A1/en not_active Abandoned
-
2013
- 2013-07-18 JP JP2013149286A patent/JP5736421B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-23 US US15/903,559 patent/US20180177839A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508333A5 (enExample) | ||
| Sher et al. | Valproic acid for treatment of hyperactive or mixed delirium: rationale and literature review | |
| Perez-Lloret et al. | Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease | |
| JP4634008B2 (ja) | ２ｈ−ベンズイミダゾール−２−オン、１，３−ジヒドロ−１−（２−｛４−［３−（トリフルオロメチル）フェニル］−１−ピペラジニル｝エチル）−及びその生理学的に許容される酸付加塩の新規使用 | |
| BR112019025286A2 (pt) | Métodos e composições para tratamento de sonolência excessiva | |
| Fenelon et al. | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study | |
| AU2002310813A1 (en) | Flibanserin for the treatment of extrapyramidal movement disorders | |
| Trotti et al. | Melatonin for sleep disorders in patients with neurodegenerative diseases | |
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| CA2461703A1 (en) | Modulation of physiological processes and agents useful for same | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| US20250302773A1 (en) | Compositions comprising meai and n-acylethanolamines and uses thereof | |
| EP3302493B1 (en) | Inhibitors of cystine-glutamate transporter for use in treating or preventing substance-related and addictive disorders | |
| Verrillo et al. | Effects of replacement therapy on sleep architecture in children with growth hormone deficiency | |
| Domino et al. | Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys | |
| HRP20171299T1 (hr) | Kombinacije s peptidom s cikliziranom okosnicom | |
| Al-Mahrouqi et al. | Crippling side effects induced by paliperidone palmitate treatment: a case report | |
| Kokane et al. | Impact of early life ketamine exposure on the developing brain and cognitive sequelae: a discussion of apoptotic neurodegeneration mechanisms | |
| Grosset | Dopamine agonists and therapy compliance | |
| Faraz et al. | Effect of Hypothyroidism on Motor Nerve Conduction Studies: A Cross Sectional Study | |
| Romeyke et al. | Integration of Cannabis Extract Tetrahydrocannabinol: Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder | |
| KR20230058615A (ko) | 파킨슨병의 운동 합병증 치료약 | |
| JP6867943B2 (ja) | レビー小体病の治療および／または予防剤 | |
| Dal Sasso et al. | The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils | |
| Abrahamowicz et al. | Vaginal application of orodispersible drugs for schizophrenia presenting with agitation and aggression. |